Granpool Innovative Investments and Environmental Technologies Fund backed the round, which will support global expansion and technology development.
"The microbiome is a megatrend that is evolving very quickly, and we are the forefront of associated discovery with our unique solution to address the enterprise data challenge. We have our sights set too on other complex data challenges including CRISPR and quantum biological challenges, such as understanding the immune response more fully. The potential is phenomenal, and we are immensely grateful to our supporters for sharing our vision and helping us to scale at this pivotal time."
The Series A round was led by Northpond Ventures and Octopus Ventures to help bring the company manufacturing platform to market.
"Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs,"
Clearstream and the Luxembourg Stock Exchange led the financing round to support the development of automated debt issuance solutions.
"We are very excited and proud to have the confidence of Clearstream and LuxSE in this transaction. This step is a fantastic validation of not just our technology, but also of the impact we have already had on the market and most importantly our customers. We look forward to working together with our new partners to make debt issuance cheaper, faster, and better for all market participants."
